CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Leukemia. 2024 Jul;38(7):1621-1625. doi: 10.1038/s41375-024-02290-y. Epub 2024 Jun 3.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CD28 Antigens*
  • CD8-Positive T-Lymphocytes / immunology
  • Humans
  • Induction Chemotherapy
  • Male
  • Multiple Myeloma* / drug therapy
  • Multiple Myeloma* / immunology
  • Multiple Myeloma* / mortality
  • Multiple Myeloma* / pathology
  • Prognosis
  • Progression-Free Survival
  • Survival Rate
  • T-Lymphocytes, Regulatory* / immunology

Substances

  • CD28 Antigens